Staar Surgical Co (STAA) 5.56 $STAA
Lifshitz & Miller Law Firm Announces Investigation of Exterran Corporation, inContact, Inc., LinkedIn Corporation, Mines Management, Inc., Rose Rock Midstream, L.P., STAAR Surgical Company, XenoPort, Inc. and Your Community Bankshares, Inc.
PR Newswire - Mon Jun 20, 11:52AM CDT
Exterran Corporation (EXTN) Lifshitz & Miller announces investigation on behalf of Exterran investors. Specifically, on April 26, 2016, Exterran announced it will restate its consolidated and combined financial statements for 2015 and expects to delay the filing of its Form 10-Q for the quarter ended March 31, 2016.
EXTN: 11.70 (+0.35), LNKD: 190.38 (+0.06), SAAS: 13.84 (+0.03), STAA: 5.56 (+0.30), YCB: 37.75 (+0.26), RRMS: 26.48 (+1.41), MGN: 1.00 (-0.01), XNPT: 7.01 (unch)
The Shuman Law Firm Investigates STAAR Surgical Company
BusinessWire - Thu Jun 09, 1:00PM CDT
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of STAAR Surgical Company ("STAAR" or the "Company"
(Nasdaq: STAA). STAAR is a Monrovia, CA-based company that designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye.
STAA: 5.56 (+0.30)
Update in Lawsuit for Investors in STAAR Surgical Company (NASDAQ:STAA) shares announced by Shareholders Foundation
GlobeNewswire - Tue May 17, 8:45AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit is pending in California on behalf of certain purchasers of shares of STAAR Surgical Company (NASDAQ:STAA) over alleged Securities Laws Violations by STAAR Surgical.
STAA: 5.56 (+0.30)
STAAR Surgical Announces Approval By Health Canada of Its EVO Visian ICL(TM) for Surgeons and Their Patients in Canada
PR Newswire - Fri May 13, 6:00AM CDT
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, was notified yesterday of the approval of its EVO Visian ICL, STAAR's Implantable Collamer® Lens, for distribution in Canada by the Medical Devices Bureau of Health Canada.
STAA: 5.56 (+0.30)
Downgrade Alert for STAAR Surgical (STAA)
Comtex SmarTrend(R) - Fri May 13, 3:24AM CDT
STAAR Surgical (NASDAQ:STAA) was downgraded from Overweight to Equal Weight at Stephens today. The stock closed yesterday at $5.65 on volume of 682,000 shares, above average daily volume of 88,000. Over the past year, STAAR Surgical has traded in a range of $6.00 to $10.76 and closed yesterday at $5.65, -6% above that low. The 200-day and 50-day moving averages have moved 0.47% lower and 1.50% higher over the past week, respectively.
STAA: 5.56 (+0.30)
Staar Surgical reports 1Q loss
Automated Insights - Wed May 11, 3:18PM CDT
MONROVIA, Calif. (AP) _ Staar Surgical Co. (STAA) on Wednesday reported a loss of $8 million in its first quarter.
STAA: 5.56 (+0.30)
STAAR Surgical Reports First Quarter 2016 Results
PR Newswire - Wed May 11, 3:01PM CDT
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye today reported financial results for the first quarter ended April 1, 2016.
STAA: 5.56 (+0.30)
Akers Biosciences (AKER) Q1 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:52AM CDT
Akers Biosciences Inc (AKER) is expected to report first-quarter 2016 results on May 12.
CAPR: 4.15 (-0.12), STAA: 5.56 (+0.30), AKER: 2.10 (-0.03), VBLT: 4.20 (+0.24)
STAAR Surgical to Report First Quarter Results on May 11, 2016
PR Newswire - Tue Apr 26, 12:14PM CDT
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today announced that it will release financial results for the first quarter ended April 1, 2016 and provide an update on activities at this year's ASCRS annual meeting on Wednesday, May 11, 2016 after the market close.
STAA: 5.56 (+0.30)
VWR Corp: Balanced Organic Growth Buoys Q4, Forex Hurts
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 1:45PM CST
On Mar 2, 2016, we issued an updated research report on VWR Corporation (VWR).
VWR: 30.00 (-0.03), STAA: 5.56 (+0.30), HSIC: 176.66 (+1.71), COO: 166.27 (+1.72)
STAAR Surgical Posts Break-Even Q4 Earnings, Sales Rise
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 8:50AM CST
STAAR Surgical Company (STAA) reported breakeven (including stock-based compensation) in the fourth quarter of 2015, which was narrower than the Zacks Consensus Estimate of a loss of 2 cents.
DSCI: 3.99 (unch), STAA: 5.56 (+0.30), HSIC: 176.66 (+1.71), COO: 166.27 (+1.72)
Becton, Dickinson's Blood Collection Set Receives FDA Nod
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 2:05PM CST
Becton, Dickinson and Company (BDX) recently announced that its new BD Vacutainer UltraTouch Push Button Blood Collection Set has received FDA approval as well as European CE marking.
BDX: 171.33 (+1.36), STAA: 5.56 (+0.30), PDCO: 48.26 (+0.36), MMSI: 19.47 (+0.49)
STAAR Surgical Has Returned 15.4% Since SmarTrend Recommendation (STAA)
Comtex SmarTrend(R) - Fri Feb 19, 12:32PM CST
SmarTrend identified a Downtrend for STAAR Surgical (NASDAQ:STAA) on October 27th, 2015 at $7.39. In approximately 4 months, STAAR Surgical has returned 15.37% as of today's recent price of $6.25.
STAA: 5.56 (+0.30)
How STAAR Surgical (STAA) Stock Stands Out in a Strong Industry
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:41AM CST
STAAR Surgical is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
STAA: 5.56 (+0.30)
16.3% Return Seen to Date on SmarTrend STAAR Surgical Call (STAA)
Comtex SmarTrend(R) - Tue Feb 09, 10:34AM CST
SmarTrend identified a Downtrend for STAAR Surgical (NASDAQ:STAA) on October 27th, 2015 at $7.39. In approximately 4 months, STAAR Surgical has returned 16.32% as of today's recent price of $6.18.
STAA: 5.56 (+0.30)
STAAR Surgical Company and Memira Holding Announce Cooperation Agreement for Memira's Eye Clinics throughout Scandinavia
PR Newswire - Tue Feb 09, 6:00AM CST
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, and Memira Holding, Sweden, today announced they have entered into an agreement effective January 1, 2016, to provide STAAR's phakic intraocular lenses (ICL) as a primary and premium option for refractive eye treatment.
STAA: 5.56 (+0.30)
Commit To Buy Staar Surgical At $5, Earn 14.9% Annualized Using Options
StockOptionsChannel.com - Mon Feb 08, 10:46AM CST
Investors eyeing a purchase of Staar Surgical Co. shares, but cautious about paying the going market price of $6.14/share, might benefit from considering selling puts among the alternative strategies at their disposal.
STAA: 5.56 (+0.30)
Lifshitz & Miller Law Firm Announces Investigation of Exterran Corporation, inContact, Inc., LinkedIn Corporation, Mines Management, Inc., Rose Rock Midstream, L.P., STAAR Surgical Company, XenoPort, Inc. and Your Community Bankshares, Inc.
PR Newswire - Mon Jun 20, 11:52AM CDT
Exterran Corporation (EXTN) Lifshitz & Miller announces investigation on behalf of Exterran investors. Specifically, on April 26, 2016, Exterran announced it will restate its consolidated and combined financial statements for 2015 and expects to delay the filing of its Form 10-Q for the quarter ended March 31, 2016.
EXTN: 11.70 (+0.35), LNKD: 190.38 (+0.06), SAAS: 13.84 (+0.03), STAA: 5.56 (+0.30), YCB: 37.75 (+0.26), RRMS: 26.48 (+1.41), MGN: 1.00 (-0.01), XNPT: 7.01 (unch)
The Shuman Law Firm Investigates STAAR Surgical Company
BusinessWire - Thu Jun 09, 1:00PM CDT
The Shuman Law Firm announces that it is investigating potential claims against certain officers and directors of STAAR Surgical Company ("STAAR" or the "Company"
(Nasdaq: STAA). STAAR is a Monrovia, CA-based company that designs, develops, manufactures, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. STAA: 5.56 (+0.30)
Update in Lawsuit for Investors in STAAR Surgical Company (NASDAQ:STAA) shares announced by Shareholders Foundation
GlobeNewswire - Tue May 17, 8:45AM CDT
The Shareholders Foundation, Inc. announces that a lawsuit is pending in California on behalf of certain purchasers of shares of STAAR Surgical Company (NASDAQ:STAA) over alleged Securities Laws Violations by STAAR Surgical.
STAA: 5.56 (+0.30)
STAAR Surgical Announces Approval By Health Canada of Its EVO Visian ICL(TM) for Surgeons and Their Patients in Canada
PR Newswire - Fri May 13, 6:00AM CDT
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, was notified yesterday of the approval of its EVO Visian ICL, STAAR's Implantable Collamer® Lens, for distribution in Canada by the Medical Devices Bureau of Health Canada.
STAA: 5.56 (+0.30)
Downgrade Alert for STAAR Surgical (STAA)
Comtex SmarTrend(R) - Fri May 13, 3:24AM CDT
STAAR Surgical (NASDAQ:STAA) was downgraded from Overweight to Equal Weight at Stephens today. The stock closed yesterday at $5.65 on volume of 682,000 shares, above average daily volume of 88,000. Over the past year, STAAR Surgical has traded in a range of $6.00 to $10.76 and closed yesterday at $5.65, -6% above that low. The 200-day and 50-day moving averages have moved 0.47% lower and 1.50% higher over the past week, respectively.
STAA: 5.56 (+0.30)
Staar Surgical reports 1Q loss
Automated Insights - Wed May 11, 3:18PM CDT
MONROVIA, Calif. (AP) _ Staar Surgical Co. (STAA) on Wednesday reported a loss of $8 million in its first quarter.
STAA: 5.56 (+0.30)
STAAR Surgical Reports First Quarter 2016 Results
PR Newswire - Wed May 11, 3:01PM CDT
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye today reported financial results for the first quarter ended April 1, 2016.
STAA: 5.56 (+0.30)
Akers Biosciences (AKER) Q1 Earnings: What's in Store?
Zacks Equity Research - Zacks Investment Research - Mon May 09, 7:52AM CDT
Akers Biosciences Inc (AKER) is expected to report first-quarter 2016 results on May 12.
CAPR: 4.15 (-0.12), STAA: 5.56 (+0.30), AKER: 2.10 (-0.03), VBLT: 4.20 (+0.24)
STAAR Surgical to Report First Quarter Results on May 11, 2016
PR Newswire - Tue Apr 26, 12:14PM CDT
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, today announced that it will release financial results for the first quarter ended April 1, 2016 and provide an update on activities at this year's ASCRS annual meeting on Wednesday, May 11, 2016 after the market close.
STAA: 5.56 (+0.30)
VWR Corp: Balanced Organic Growth Buoys Q4, Forex Hurts
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 1:45PM CST
On Mar 2, 2016, we issued an updated research report on VWR Corporation (VWR).
VWR: 30.00 (-0.03), STAA: 5.56 (+0.30), HSIC: 176.66 (+1.71), COO: 166.27 (+1.72)
STAAR Surgical Posts Break-Even Q4 Earnings, Sales Rise
Zacks Equity Research - Zacks Investment Research - Thu Mar 03, 8:50AM CST
STAAR Surgical Company (STAA) reported breakeven (including stock-based compensation) in the fourth quarter of 2015, which was narrower than the Zacks Consensus Estimate of a loss of 2 cents.
DSCI: 3.99 (unch), STAA: 5.56 (+0.30), HSIC: 176.66 (+1.71), COO: 166.27 (+1.72)
Becton, Dickinson's Blood Collection Set Receives FDA Nod
Zacks Equity Research - Zacks Investment Research - Fri Feb 19, 2:05PM CST
Becton, Dickinson and Company (BDX) recently announced that its new BD Vacutainer UltraTouch Push Button Blood Collection Set has received FDA approval as well as European CE marking.
BDX: 171.33 (+1.36), STAA: 5.56 (+0.30), PDCO: 48.26 (+0.36), MMSI: 19.47 (+0.49)
STAAR Surgical Has Returned 15.4% Since SmarTrend Recommendation (STAA)
Comtex SmarTrend(R) - Fri Feb 19, 12:32PM CST
SmarTrend identified a Downtrend for STAAR Surgical (NASDAQ:STAA) on October 27th, 2015 at $7.39. In approximately 4 months, STAAR Surgical has returned 15.37% as of today's recent price of $6.25.
STAA: 5.56 (+0.30)
How STAAR Surgical (STAA) Stock Stands Out in a Strong Industry
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 7:41AM CST
STAAR Surgical is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
STAA: 5.56 (+0.30)
16.3% Return Seen to Date on SmarTrend STAAR Surgical Call (STAA)
Comtex SmarTrend(R) - Tue Feb 09, 10:34AM CST
SmarTrend identified a Downtrend for STAAR Surgical (NASDAQ:STAA) on October 27th, 2015 at $7.39. In approximately 4 months, STAAR Surgical has returned 16.32% as of today's recent price of $6.18.
STAA: 5.56 (+0.30)
STAAR Surgical Company and Memira Holding Announce Cooperation Agreement for Memira's Eye Clinics throughout Scandinavia
PR Newswire - Tue Feb 09, 6:00AM CST
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, and Memira Holding, Sweden, today announced they have entered into an agreement effective January 1, 2016, to provide STAAR's phakic intraocular lenses (ICL) as a primary and premium option for refractive eye treatment.
STAA: 5.56 (+0.30)
Commit To Buy Staar Surgical At $5, Earn 14.9% Annualized Using Options
StockOptionsChannel.com - Mon Feb 08, 10:46AM CST
Investors eyeing a purchase of Staar Surgical Co. shares, but cautious about paying the going market price of $6.14/share, might benefit from considering selling puts among the alternative strategies at their disposal.
STAA: 5.56 (+0.30)
